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Identity 
Other names: BGP; BGPI; BGP1; CD66a; BGP 
HGNC (Hugo): CEACAM1 
Location: 19q13.2 
Local order: centromere - CGM7(CEACAM4) - 
CGM2(CEACAM7) - CEA(CEACAM5) - 
NCA(CEACAM6) - CGM1(CEACAM3) - CEACAM1 
- CGM9(CEACAMP2) - CGM6(CEACAM8) - 
CGM8(CEACAMP1) - telomere. 
DNA/RNA 
Note 
The locus is complex, and it produces several proteins 
via alternative splicing. 
Description 
The gene is composed of 9 exons spanning in a region 
of 23,140 bp (Localized from 47,724,479 to 47,703,298 
from pter). 
Transcription 
Human CEACAM1 consists of 9 exons that can be 
alternatively spliced to generate 11 different isoforms. 
The gene contains 19 different introns, and the 
sequence is supported by 286 sequences from 262 
cDNA clones. The transcripts differ by truncation of 
the N-terminus, truncation of the C-terminus, presence 
or absence of a cassette exon, common exons with 
different boundaries. Among various types of isoforms, 
the full-length nature of two alternative transcripts 
(NM_001024912.1, NM_001712.3) has been 
determined. 
Pseudogene 
Eleven pseudogenes of the CEA cell adhesion molecule 
subgroup are found in the cluster of the two subgroups 
of the CEA family (the CEA cell adhesion molecules 
and the pregnancy-specific glycoproteins which locate 




Genomic structure of human CEACAM1. Open and closed boxes indicate untranslated regions and coding regions (exons) of CEACAM1 
gene, respectively. The ATG initiation codon is located in the first exon, and the TGA termination codon is located in exon 9. N, A1, B1 
and A2; Ig domains, TM; transmembrane domain, C; cytoplasmic domain. 
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In human, 11 different CEACAM1 splice variants have been reported. The domain structure of each protein isoform is illustrated as open 
box. N; N-terminal immunoglobulin variable-region-like (IgV-like) domain, A or B; subsets of constant-region-type-2-like (IgC2-like) 
domains, TM; transmembrane domain, C; cytoplasmic domain. Nomenclature number after CEACAM1 indicates the number of 
extracellular immunoglobulin-like domains, whereas the letter that follows this indicates the presence of either a long (L) or a short (S) 
cytoplasmic tail, a unique termini (C), or an Alu family repeat sequence present within the open reading frame (A). For example, 
CEACAM1 with four extracellular immunoglobulin-like domains and with a long cytoplasmic domain is called as CEACAM1-4L. The most 




CEACAM1 is a single-pass type-1 glycoprotein which 
belongs within the Ig gene superfamily. It contains a 34 
amino acid (aa) leader sequence, an extracellular 
domain which contains a N-terminal IgV-like domain 
and three of IgC2-like domains (382 aa), a 
transmembrane domain (43 aa), a cytoplasmic domain 
(67 aa) and two of the potential tyrosine 
phosphorylation sites. CEACAM1 is heavily N-
glycosylated with more than 60% of the mass 
contributed by N-linked glycans. 
Localisation 
CEACAM1 isoforms with transmembrane domain are 
mostly cell-membrane anchored, whereas those without 
transmembrane domain are secreted. They are mostly 
expressed in cells of epithelial and endothelial, 
lymphoid and myeloid cells. 
Function 
CEACAM1 is capable of homophilic with CEACAM1 
or heterophilic adhesion with CEA and CEACAM6. 
Isoforms of CEACAM1 with a long cytoplasmic 
domain generally transmit inhibitory signals, whereas 
isoforms with a short cytoplasmic domain indicate a 
regulated interaction with the cytoskeleton. CEACAM1 
has been implicated in various types of intercellular-
adhesion and intracellular-signaling of cell survival, 
differentia-tion and growth in both normal and cancer 
cells as follows: 
(1) CEACAM1 inhibits proliferation of both epithelial 
cells and T lymphocytes by a contact-mediated 
mechanism. In monocytes, CEACAM1 regulates 
phosphatidylinositol 3-kinase (PI3K) and Akt-
dependent survival signal and inhibits apoptosis. 
(2) CEACAM1 induces apoptosis of mature 
colonocytes and mammary epithelial cells, which is in 
part of a morphogenetic process in the formation of 
glandular lumen. 
(3) CEACAM1 has been demonstrated to stimulate 
cellular migration of blood vessel endothelial cells. 
(4) In granulocytes, CEACAM1 mediates the binding 
to endothelial E-selectin. 
(5) The involvement of CEACAM1 in carcinogenesis 
is complex. In some types of cancer cells such as colon 
cancer and hepatoma loss or reduced expression of 
CEACAM1 is frequently observed, thereby it has been 
regarded as a tumor suppressor. However, in other 
types, for example, thyroid cancer and gastric cancer, 
CEACAM1 is up-regulated. 
(6) CEACAM1 exerts angiogenic properties and is a 
major effecter of VEGF in the early vascular formation. 
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Since CEACAM1 is mainly expressed in tumor 
microvessels but not in large blood vessels, it may be a 
target for the therapy of tumor angio-genesis. 
(7) Neisseria gonorrhea triggers expression of 
CEACAM1 on primary endothelial cells by activating 
the immediate early response trans-cription factor NF-
kappaB.  
Neisseria gonorrhoeae colony opacity-associated (Opa) 
proteins bind to human CEACAM on host cells 
including T lymphocytes, and Opa binding to 
CEACAM1 suppresses the activation of CD4+ T cells 
in response to a variety of stimuli.(8) CEACAM1 
regulates insulin clearance in the liver. 
Homology 
CEACAM1 is the human homolog of a cell adhesion 
molecule (CAM) of the rat designated Cell-CAM. 
Rattus norvegicus: 70.74 (n), 56.12(a) (Percentage 
Identity). 




CEACAM1 mRNA was demonstrated to be down-
regulated to < or = 0.4 in 80% of 21 colorectal 
carcinoma tissue specimens as compared with the 
respective adjacent normal mucosa (Neumaier et al., 
1993). CEACAM1 was reported to be associa-ted with 
pp60c-src, suggesting that down-regulation of 
CEACAM1 in about 80% of colorectal carcino-mas 
may contribute to a dysfunction of pp60c-src in 
colorectal cancer (Brummer et al., 1995). 
Hepatocellular carcinoma 
Note 
CEACAM1 was reported to be diffusely expressed in 
113 of 139 hepatomas. Loss of CEACAM1 expression 
was closely associated with large tumor size, 
multiplicity of the tumor, portal vein invasion, and 
satellite nodules and affected survival adversely, 
according to univariate (P < 0.0001) and multivariate 
analyses (relative risk, 5.737; P < 0.001) (Cruz et al., 
2005). In rat hepatoma cells 1682A, restoration of 
CEACAM1-4L expression was demonstrated to 
completely suppress the tumor formation (Laurie et al., 
2005). In human hepatoma cell lines (HLF, 
PLC/PRF/5, HepG2 and KYN-2), CEACAM1 protein 
was demonstrated to only express in HepG2, which 
shows a strong property for enhanced anchorage-
independent growth. It was reported that CEACAM1 
acts as a tumor suppressor when the cells are cultured 
in anchorage-dependent growth conditions. In contrast, 
in anchorage-independent growth conditions, 
CEACAM1 augments cell proliferation by potentiating 
the cell-cell attachment (Hokari et al., 2007). 
Breast cancer 
Note 
CEACAM1 is down-regulated in around 30% of breast 
cancers. CEACAM1 is reported to suppress the 
tumorigenicity of breast cancer cells via its cytoplasmic 
domain but not the extracellular domain (Luo et al., 
1997). CEACAM1 is demonstrated to be consistently 
expressed in normal tissue and benign lesions of 
mammary gland, whereas it disappears with the 
development of the malignant phenotype in both 
noninvasive and invasive carcinoma (Riethdorf et al., 
1997). CEACAM1 is reported to be expressed at high 
levels in cribiform ductal carcinoma in situ (DCIS). 
Although most invasive ductal carcinomas express 
CEACAM1 weakly, tumours with minimal lumena 
formation show cytoplasmic CEACAM1 expression 
(Kirshner et al., 2004). 
Prostate cancer 
Note 
CEACAM1 is reported to be regulated by androgen and 
might act as a growth repressor during differentiation 
of the prostatic epithelium. Forced expression of 
CEACAM1 results in the significan-tly lower growth 




CEACAM1 is expressed in umbrella cells of bladder 
urothelium, but is down-regulated in superficial bladder 
cancer. CEACAM1 silencing in bladder cancer cell 
lines 486p and RT4 using the small interfering RNA 
technique leads to a significant up-regulation of 
vascular endothelial growth factor (VEGF)-C and 
VEGF-D, suggesting that the epithelial down-
regulation of CEACAM1 induces angiogenesis via 
increased expression of VEGF-C and VEGF-D 
(Oliveira-Ferrer et al., 2004). 
Melanoma 
Note 
A total of 28 of 40 patients with CEACAM1-positive 
primary melanomas developed metastatic disease, 
compared with only six of 60 patients with 
CEACAM1-negative melanomas. the strongest 
CEACAM1 expression was observed at the invading 
front. Kaplan-Meier analysis revealed a highly 
significant association between CEACAM1 expression 
and metastasis (P <.0001) (Thies et al., 2002). 
Renal cell carcinoma 
Note 
In normal kidney, CEACAM1 was found in epithelial 
cells of proximal tubules and in endothel-ial cells. In  
contrast, tumour cells of 30 clear cell, three 
chromophobic, and two chromophilic RCCs were  
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completely devoid of CEACAM1. Renal adenomas 
also lacked CEACAM1 expression. Similarly, RCC 
cell lines CaKi1, CaKi2, A498, and RCC26 exhibited 
no or low-level CEACAM1 expression. However, 
CEACAM1 expression was transiently induced in 
A498 cells upon contact with allogeneic CD8+ T cells, 
mediated at least in part by interferon-gamma. 
Furthermore, the majority of tumour-infiltrating T and 
NK cells expressed CEACAM1 upon stimulation. 
Thus, transient expression of the tumour suppressor 
CEACAM1 by tumour cells and subsequent 
homophilic interaction with CEACAM1 on tumour-
infiltrating lympho-cytes could represent a novel 
immune escape mechanism in RCC (Kammerer et al., 
2004). 
To be noted 
Note 
The role of CEACAM1 in cancer may be different 
among different types of cancer. CEACAM1 is down-
regulated in colon carcinomas, hepatocellular 
carcinomas, a proportion of breast cancers. In contrast, 
in prostate cancer and bladder cancer, CEACAM1 is 
down-regulated in the cancer cells, whereas 
overexpressed in blood microvessels and lymphatic 
capillaries and in the vicinity of the tumor. In thyroid 
cancer, gastric cancer and metastasing malignant 
melanomas, CEACAM1 is increased. 
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